Publications

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2778

Evaluation of the Staphylococcus aureus Analysis “1928D” Pipeline to Determine the Epidemiological Threshold Using Whole Genome Sequence Data. Lead author: LM Deshpande, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2686

Azole Resistance in Candida parapsilosis and Candida tropicalis from a Global Surveillance is Mainly Caused by Alterations in Erg11 and MDR1 Overexpression. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2162

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2783

Synergistic Activity of Colistin and Zidovudine (AZT) Combinations against Colistin-Resistant Enterobacteriaceae. Lead author: LR Duncan, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2787

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1847

Antimicrobial Activity of Plazomicin Tested against Enterobacteriaceae Isolates from European Medical Centres Stratified by Infection Type (2014-2017). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1873

Antimicrobial Activity of POL7306 Tested against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1843

Plazomicin Activity against Enterobacteriaceae Isolates Carrying Genes Encoding Extended-Spectrum β-Lactamases, Carbapenemases, and/or Aminoglycoside-Modifying Enzymes. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1872

Activity of Tedizolid and Comparators against Enterococcus spp. that Include Multidrug-Resistant Clinical Isolates from European and US Medical Centres (2016-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1883

In Vitro Activity of Omadacycline and Comparators against Recent Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1876

Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1882

In Vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecularly Characterized β-Lactamase Genes. Lead author: RE Mendes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1180

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1171

In Vitro Activity of the Extended-Spectrum β-Lactamase Inhibitor Enmetazobactam (formerly AAI101), in Combination with Cefepime, against 90 Moleculary Characterized Enterobacteriaceae Isolates Expressing a Variety of Non-β-Lactam Resistance Mechanisms. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1170

Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America in 2015-2016. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1199

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Patients at Risk of Infections Caused by Resistant Gram-Negative Pathogens. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1191

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centres in Europe and the Asia-Pacific Region (2018). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1174

Cefepime-Zidebactam (WCK 5222) Activity When Tested against Gram-Negative Organisms Isolated from Patients Hospitalized in Europe and the Asia-Pacific Region in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1172

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against European Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1189

Activity of Meropenem-Vaborbactam and Single-Agent Comparators against KPC-Producing Enterobacterales Isolates from European Countries (2016-2018) Stratified by Infection Type. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#L0041